Copper(II)-bis(thiosemicarbazonato) complexes as anti-chlamydial agents

Marsh, JW; Djoko, KY; McEwan, AG; Huston, WM

Copper(II)-bis(thiosemicarbazonato) complexes as anti-chlamydial agents

Marsh, JW

Djoko, KY McEwan, AG Huston, WM

Permalink

Publication Type:: Journal Article
Citation:: Pathogens and Disease, 2017, 75 (7)
Issue Date:: 2017-10-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Accepted ManuscriptAdobe PDF (461.71 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Marsh, JW https://orcid.org/0000-0003-4681-1012	en_US
dc.contributor.author	Djoko, KY	en_US
dc.contributor.author	McEwan, AG	en_US
dc.contributor.author	Huston, WM https://orcid.org/0000-0002-0879-1287	en_US
dc.date.available	2020-05-25T19:07:13Z
dc.date.issued	2017-10-01	en_US
dc.identifier.citation	Pathogens and Disease, 2017, 75 (7)	en_US
dc.identifier.uri	http://hdl.handle.net/10453/115586
dc.description.abstract	© FEMS 2017. Lipophilic copper (Cu)-containing complexes have shown promising antibacterial activity against a range of bacterial pathogens. To examine the susceptibility of the intracellular human pathogen Chlamydia trachomatis to copper complexes containing bis(thiosemicarbazone) ligands [Cu(btsc)], we tested the in vitro effect of CuII-diacetyl- and CuII-glyoxal-bis[N(4)-methylthiosemicarbazonato] (Cu(atsm) and Cu(gtsm), respectively) on C. trachomatis. Cu(atsm) and to a greater extent, Cu(gtsm), prevented the formation of infectious chlamydial progeny. Impacts on host cell viability and respiration were also observed in addition to the Chlamydia impacts. This work suggests that copper-based complexes may represent a new lead approach for future development of new therapeutics against chlamydial infections, although host cell impacts need to be fully explored.	en_US
dc.relation.ispartof	Pathogens and Disease	en_US
dc.relation.isbasedon	10.1093/femspd/ftx084	en_US
dc.subject.mesh	B-Lymphocytes	en_US
dc.subject.mesh	Cell Line	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Chlamydia trachomatis	en_US
dc.subject.mesh	Cations, Divalent	en_US
dc.subject.mesh	Copper	en_US
dc.subject.mesh	Thiosemicarbazones	en_US
dc.subject.mesh	Anti-Bacterial Agents	en_US
dc.subject.mesh	Cell Respiration	en_US
dc.subject.mesh	Cell Survival	en_US
dc.subject.mesh	Dose-Response Relationship, Drug	en_US
dc.subject.mesh	Host-Pathogen Interactions	en_US
dc.subject.mesh	Coordination Complexes	en_US
dc.title	Copper(II)-bis(thiosemicarbazonato) complexes as anti-chlamydial agents	en_US
dc.type	Journal Article
utslib.citation.volume	7	en_US
utslib.citation.volume	75	en_US
utslib.for	1101 Medical Biochemistry and Metabolomics	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Strength - ithree - Institute of Infection, Immunity and Innovation
utslib.copyright.status	open_access
pubs.issue	7	en_US
pubs.publication-status	Published	en_US
pubs.volume	75	en_US

Abstract:

© FEMS 2017. Lipophilic copper (Cu)-containing complexes have shown promising antibacterial activity against a range of bacterial pathogens. To examine the susceptibility of the intracellular human pathogen Chlamydia trachomatis to copper complexes containing bis(thiosemicarbazone) ligands [Cu(btsc)], we tested the in vitro effect of CuII-diacetyl- and CuII-glyoxal-bis[N(4)-methylthiosemicarbazonato] (Cu(atsm) and Cu(gtsm), respectively) on C. trachomatis. Cu(atsm) and to a greater extent, Cu(gtsm), prevented the formation of infectious chlamydial progeny. Impacts on host cell viability and respiration were also observed in addition to the Chlamydia impacts. This work suggests that copper-based complexes may represent a new lead approach for future development of new therapeutics against chlamydial infections, although host cell impacts need to be fully explored.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/115586